5/22/2013 9:02:06 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Covidien champions positive results for the Barrett's esophagus ablation device it acquired along with Barrx in 2011. Covidien (NYSE:COV) touted study results showing that the Barrett's esophagus treatment it acquired along with Barrx 2 years ago reduces pre-cancerous tissue.
Help employers find you! Check out all the jobs and post your resume.
comments powered by